

October 30, 2008

**RESEARCH PERSONNEL NOTIFICATION OF PHARMACY BENEFITS
MANAGEMENT DRUG SAFETY ALERTS AND ADVERSE DRUG EVENTS
RELATED TO INTERVENTIONAL HUMAN SUBJECTS RESEARCH STUDIES**

1. PURPOSE. This Veterans Health Administration (VHA) Directive establishes policy and procedures that will ensure that the investigators, Associate Chiefs of Staff for Research and Development (ACOS for R&D), Administrative Officers for Research and Development (AO for R&D), and Institutional Review Boards (IRBs) are notified as soon as possible about all Department of Veterans Affairs (VA) Pharmacy Benefits Management (PBM) Services alerts. These alerts include safety issues and adverse events related to Food and Drug Administration (FDA) approved medications and biologics used in human research projects conducted by VA. This early notification of the ACOS for R&D, AO for R&D, investigator, and Chiefs of Pharmacy Services will allow for a timely assessment of risks to research subjects and, when indicated, modifications in research protocols, informed consent, and prompt notification of research participants to ensure the highest level of protections for these research subjects. It will also serve to alert investigators to the need for the reporting, monitoring, and surveillance of adverse drug events (ADEs), whether they were observed Adverse Drug Reactions (ADR) or historical ADRs from FDA approved investigational drugs. This notification will ensure timely inclusion of patient or research subject information to the national VA Adverse Drug Event Reporting System (VA ADERS), the newly formed VA ADERS Advisory Committee (VA ADERS AC), and the FDA MedWatch System.

2. BACKGROUND

a. PBM notifications of safety issues and adverse events related to pharmaceuticals have long been available to VHA clinicians. However, there has been no formal mechanism to ensure direct dissemination of such information to the VA research community including, when appropriate, research participants.

b. Definitions

(1) **Adverse Drug Event (ADE).** An ADE is an injury from the use of a drug. Under this definition, the term ADE includes harm caused by the drug (adverse drug reactions and overdoses) and harm from the use of the drug including dose reductions and discontinuation of drug therapy. An ADE is a response to a drug which is noxious and unintended and which occurs at doses normally used in people for prophylaxis, diagnosis, or therapy of disease or for the modification of physiologic function. It can be a causal or suspected link between a drug or adverse drug reaction. However, causality or association of the drug to the adverse drug reaction does not have to be established in order to report an adverse drug reaction or adverse drug event.

THIS VHA DIRECTIVE EXPIRES OCTOBER 31, 2013

October 30, 2008

(2) **Adverse Drug Reaction (ADR).** A response to a drug which is noxious and unintended and which occurs at doses normally used in people for prophylaxis, diagnosis, or therapy of disease or for the modification of physiologic function.

(a) **Observed ADR.** Defined in the Computerized Patient Record System (CPRS) as a reaction that is “directly observed or occurring while the patient was on the suspected causative agent.” Observed refers to a newly noted adverse outcome, typically within the past 3 months. Although the term implies that the provider of record made the diagnosis, the fact that a provider may not have visually observed an ADR does not preclude reporting as observed.

(b) **Historical ADR.** An event that occurred greater than 3 months prior to or that reportedly occurred in the past at another healthcare setting. It is defined in the system as “reported by the patient as occurring in the past: no longer requires intervention.”

(c) **Allergy.** An adverse drug reaction mediated by an immune response (e.g. rash, hives).

(d) **Side Effect.** A side effect is an expected and known effect of a drug that is not the intended therapeutic outcome. The term side effect tends to nominalize the concept of injury from the drug. It is recommended that the term should generally be avoided in favor of ADR.

(e) **Mild ADE Severity.** An event that requires minimal therapeutic intervention such as discontinuation of drugs.

(f) **Moderate ADE Severity.** An event that requires active treatment of adverse reaction or further testing or evaluation to assess extent of non-serious outcome.

(g) **Serious ADE Severity.** An event is serious when the patient outcome is: death, life-threatening, hospitalization (initial or prolonged), disability or permanent damage, congenital anomaly or birth defect, required intervention to prevent permanent impairment or damage, other serious or important medical events. It may result in an organ threatening situation, significant or permanent disability, requiring interventions to prevent permanent impairment or damage, or prolonged hospitalization or death.

(3) **Comparator Drug.** A comparator drug is an agent that the investigational drug is being compared to in a clinical trial. A comparator drug may be the current standard of care for the disease state being studied.

(4) **Investigational Drug.** An investigational drug is a chemical or biological drug that is used in a clinical investigation. An investigational drug can be a new chemical compound which has not been released by the FDA for general use, or an approved drug that is being studied for an approved or unapproved use, dose, dosage form, or administration schedule, under an Investigational New Drug (IND) application, in a controlled, randomized, or blinded clinical trial.

(5) **National PBM Bulletin.** A National PBM Bulletin is a Drug Safety Alert that includes standard sections: Issue, Background, Recommendations, and References. It is disseminated by PBM to the Drug Safety Alert Mail Group within 10 business days of receipt of notification from the FDA or other credible source, once sufficient evidence has been collected. The recommended actions in a National PBM Bulletin include provider notification as well as actions to be carried out by the provider. When warranted, recommended actions include patient notifications by phone call, in person or by letter. Confirmation that actions have been completed will be required.

(6) **National PBM Communication.** A National PBM Communication is a Drug Safety Alert that does not include standard sections, but is warranted to further clarify and/or emphasize what is noted in the drug-related safety information. It is disseminated by PBM to the Drug Safety Alert Mail Group within 10 business days of receipt of notification from the FDA or other credible source, once sufficient evidence has been collected. The recommended actions in a National PBM Communication include provider notification and when warranted, patient notifications by phone call, in person or by letter. Confirmation that actions have been completed will be required.

(7) **Study-related Drugs.** Any specific molecular entity that is related to a study outcome and is specifically mentioned in the research informed consent documents.

3. POLICY. It is VHA policy that each VA facility conducting human subjects research must establish standard operating procedures (SOPs) that ensure rapid notification of investigators, ACOS for R&D, AO for R&D, IRBs, and Research and Development Committees of relevant National PBM Bulletins and National PBM Communication Drug Safety Alerts. These SOPs must, when required, ensure appropriate notification of research subjects involved, and appropriate modifications to the research protocol and informed consent to ensure the highest level of protections for the research subjects. **NOTE:** *This policy applies to all VA-approved interventional human research studies, (i.e., studies that gather data thorough interactions with subjects).*

4. ACTIONS

a. **Office of Research Oversight (ORO).** ORO is responsible for overseeing compliance with this Directive.

b. **Office of Research and Development (ORD).** ORD must approve any notification recommendation for discontinuing an investigational drug, a comparator drug, or a drug that is named in the research informed consent.

c. **VISN Director.** The VISN Director is responsible for ensuring that any required communication to PBM or VAMedSaFE, as directed in National PBM Bulletin or National PBM Communication documents, occurs. **NOTE:** *Responses are required within 10 business days of receipt.*

VHA DIRECTIVE 2007-072

October 30, 2008

d. **Facility Director.** The facility Director is responsible for:

(1) Ensuring the applicable facility level policies are developed that address the requirements in this Directive.

(2) Disseminating all Drug Safety Alert documents within the facility.

(3) Confirming document dissemination and follow-up action to the VISN Director when required.

(4) Ensuring that the VA Investigator or clinician documents in CPRS any observed ADEs that occurred or were recognized in association with any FDA-approved drug or biologic used in a research study.

(5) Ensuring that all VA investigators or clinicians involved in direct patient care receive employee health care orientation training on entering ADEs into CPRS and VA ADERS of any FDA approved drug or biologic.

(6) Ensuring participation of research staff with appropriate departments or groups involved in the ADE process for the coordination of ADE reporting and risk assessments.

e. **Chief of Staff (COS).** The COS is responsible for:

(1) Disseminating all Drug Safety Alerts and related materials to the Associate Chief of Staff (ACOS) for Research and Development (R&D)

(2) Verifying that all required actions have been completed including mailing of patient or subject letters, and the appropriate documentation of all actions has been completed.

(3) Reporting to the facility Director that all research subjects have been notified when notification is required.

f. **Facility Chief, Pharmacy Service.** In addition to those responsibilities found in VHA Handbook 1108.04, the Chief of the facility's Pharmacy Service is responsible for:

(1) Maintaining current records of all pharmaceutical products that are being used as either investigational drugs or comparator drugs.

(2) Designating a research pharmacist to serve as liaison to the facilities research program in areas such as; the use of a study related drugs, evaluation of the impact of the research on the Pharmacy Service, and review of the research protocol.

(3) Serving as a subject matter expert for the IRB when necessary.

g. **ACOS for R&D and AO for R&D.** The ACOS for R&D and AO for R&D are responsible for:

(1) Maintaining a current list of all investigational drugs, comparator drugs, or study-related drugs being used in the facility's VA approved human subjects research. The list must be computerized, and must contain the name of the investigator and the study name. It must be provided electronically to the Pharmacy Service.

(2) Reviewing all National PBM Bulletins or National PBM Communications as soon as they are received.

(3) Determining whether or not the specific pharmaceuticals addressed in National PBM Bulletins or National PBM Communications are on the current list of pharmaceuticals (investigational drug, comparator drug, study-related drug) being used in any of the facility's human research protocols. If the pharmaceutical is being used in a protocol, the ACOS for R&D and AO for R&D are responsible for:

(a) Contacting the investigator (verbally and in writing) as soon as possible and always within 5 working days and forwarding a copy of the National PBM Bulletin or National PBM Communication to the IRB with the name of the study involved.

(b) Ensuring that records are maintained of all notifications and the resulting actions and communications.

(c) Determining in conjunction with the investigator, the Pharmacy Service, or other qualified individual, if the report contains information that may indicate an increased risk or potential risk to research subjects, or require changes to any part of the research protocol and informed consent. **NOTE:** *If a notification recommends discontinuing an investigational drug, a comparator drug, or a drug that is named in the research informed consent, the Office of Research and Development (ORD) must approve any such recommendation. ORD's decision must be conveyed to the IRB and the investigator.*

(4) Notifying the COS that all research subjects have been notified if notification was required, and that the notification of the research subjects was appropriately documented. If all research subjects were not notified, the COS must be informed in writing that they have not and why they were not notified.

(5) If the ACOS for R&D is not a physician, ensuring that the COS or designee is consulted regarding any determinations that are made regarding the VA-PBM safety alerts.

h. **Investigator.** Each investigator is responsible for:

(1) Determining in consultation with the ACOS for R&D, the Chief, Pharmacy Service, or other qualified individuals, whether the information in the National PBM Bulletin or National PBM Communication represents apparent immediate harm or potential increased risk to research subjects. If it is determined that there is increased risk or possible harm to research subjects:

VHA DIRECTIVE 2007-072
October 30, 2008

(a) A list of research subjects who may be at risk must be compiled.

(b) Apparent Immediate Harm to the Subjects. If it is determined that there may be a apparent immediate harm to subjects, the IRB Chair must be notified as soon as possible but within 3 working days of the investigator becoming aware of the apparent immediate harm and the following actions must be taken:

1. The protocol and informed consent must be appropriately amended immediately.

2. Modifications in the amendment may be instituted prior to IRB approval to eliminate apparent immediate harm to the research subjects. If they are instituted, the IRB Chair must be notified of the actions taken and the amended protocol and consent must be submitted to the IRB as required by VHA policy. ***NOTE:** PBM notification letter will be sent to the investigators, IRB, and Data Monitoring Committee (DMC). The DMC will convene within 5 day if practicable, and will submit a summary of their findings to the IRB within 24 hours of the meeting.*

(c) Possible Increased Risk to Research Subjects. The IRB Chair must be notified of the possible increased risk to the subject within 5 working days of the investigator becoming aware of the risk. The notification should be in the form of a memorandum or other document that discusses the new information, the risk to the subjects, and a proposed action plan. The proposed plan may include amendments to the protocol and the informed consent. ***NOTE:** If the PBM alert includes a notification letter for all patients and subjects, the letter must be submitted to the IRB for approval prior to sending it to the subjects unless there is apparent immediate harm to the research subject..*

(2) Initiating all modifications approved or required by the IRB in a timeframe required by the IRB. The implementation of these modifications must be documented in the research record and as appropriate, in the subject's medical record. The modifications or changes may include, but are not be limited to, notification of the subjects by letter or phone call, amendments to the informed consent that must be signed by the subjects, additional laboratory testing or safety monitoring, or unscheduled subject visits. ***NOTE:** It may be necessary to develop a timeline for implementation depending on the number, the complexity, and the urgency of the modifications. In addition, the documentation may need to include such issues as: when attempts at contact were made, and the content of the material provided to the subject; notation of the date and content of subject's response; dates of all successful or unsuccessful attempts to contact the subject; date when subject signed the amendment to the informed consent; and, the date and content of any oral discussion of the issue with the subject (in person or by phone).*

(3) **Responding to FDA Withdrawal of Marketed Drugs.** If a research investigational drug, comparator drug, or other drug named in the research informed consent is withdrawn from the market by FDA no new study subjects may be entered into the study. Those subjects already entered into the study will be notified to stop taking the drug, noting how the drug should be stopped, and if any additional follow-up is required.

(4) **Documenting ADE.** All ADEs in research subjects must be entered into CPRS and VA ADERS as required by VHA Directive 2008-059. All other requirements in that directive must also be followed.

i. **IRB.** IRB responsibilities include but are not limited to:

(1) **Apparent Immediate Harm to Subjects.** Upon receiving information on a National PBM Bulletin or Communication from the investigator, ACOS for R&D, or the facility's COS, that a notification may represent apparent immediate harm to subjects, the IRB Chair (or designee, as appropriate) must determine and document what steps are required to protect the human subjects from harm. *NOTE: Depending on the apparent immediate harm and the urgency to take immediate steps to prevent or reduce the magnitude of harm, the investigator may have already implemented some actions. Any actions taken by the investigator must be reported to the IRB within 3 working days.*

(a) If the IRB Chair (or designee, as appropriate) determines that specific immediate actions have not been but must be implemented, the IRB Chair (or designee as appropriate) must communicate these determinations to the investigator in a timeframe consistent with the potential for apparent immediate harm to the subject. This must also be communicated to the full IRB as required by the facility's SOPs. *NOTE: If the research subjects and/or the investigators are blinded and do not know if individual research subjects are on the medication addressed in the National PBM Bulletin or National PBM Communication because it may be either the investigational drug or comparator drug, the required notifications, re-consenting or other steps should be sent to all subjects as determined by the IRB.*

(b) Upon making its determinations, the IRB Chair (or designee as appropriate) must also notify the investigator, the R&D Committee Chair, the ACOS for R&D, the COS, and the Facility Director what steps will be taken based on the apparent immediate harm to the subjects.

(c) The investigator must be directed to initiate the required steps and the timeframe in which they must be implemented.

(2) **Possible Increased Risk to Subjects.** The IRB must review and take action on the information submitted by the investigator as required by the facility's SOPs. The information may include an amendment to the protocol or the informed. During its review the IRB must determine:

(a) If the new information provided in the notification represents increased risk to the research subjects.

(b) What, if any, communication must be sent to the research subjects (current and/or former research subjects) and in what time frame.

(c) What, if any, information must be discussed with the research subjects (current and/or former research subjects) in person and in what time frame.

(d) What, if any, changes must be made to the informed consent document and the protocol.

(e) What research protocol amendments must be made to address the risk or amend the safety plan for the study.

(f) If the amended protocol and informed consent submitted by the investigator contain all required actions or if the IRB must identify additional changes.

(3) The IRB's determinations must be conveyed in writing to the investigator in a time frame that is appropriate to the possible increased risk posed by the pharmaceutical. The notification must include a timeframe for all actions. Copies of the written communication must be filed in the IRB's records.

(4) All IRB deliberations and requirements must be recorded in the IRB records.

j. **R&D Committee.** The R&D Committee is responsible for:

(1) Reviewing the findings of the IRB and making any other appropriate recommendations.

(2) Communicating these recommendations to the investigator and the IRB. ***NOTE:** If the recommendations require an amendment to the protocol or the informed consent, these amendments must be approved by the IRB.*

(3) Documenting all recommendations and communications with the investigator and the IRB.

(4) Ensuring that the facility's research compliance officer or other designated individual, audits all aspects of the requirements of this directive to ensure compliance in the appropriate timeframe.

(5) Ensuring that the R&D Committee minutes appropriately documents all discussions and actions taken.

5. REFERENCES

a. VHA Handbook 1108.04.

b. VHA Handbook 1058.1.

c. VHA Handbook 1200.5.

d. PBM Website for Standardized Definitions of ADE's and ADRs:

<http://vaww.national.cmop.va.gov/PBM/default.aspx> . ***NOTE:** This is an internal VA website for the use of VA staff.*

6. FOLLOW-UP RESPONSIBILITY. The Office of Research and Development (12) is responsible for the contents of this Directive. Questions may be addressed to (202) 461-1700.

7. RECISSIONS. None. This VHA Directive expires October 31, 2013.

Michael J. Kussman, MD, MS, MACP
Under Secretary for Health

DISTRIBUTION: CO: E-mailed 10/30/08
FLD: VISN, MA, DO, OC, OCRO, and 200 – E-mailed 10/30/08